Toremifene in postmenopausal breast cancer. Efficacy, safety and cost

Drugs and Aging

Volumn 11, Issue 4, 1997, Pages 261-270

  Mäenpää, Juhani U ^a   Ala Fossi, Sirkka Liisa ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; DIMETHYLBENZ[A]ANTHRACENE; ESTRADIOL; ESTROGEN RECEPTOR; FOLLITROPIN; LIPID; LUTEINIZING HORMONE; PLASMA PROTEIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TAMOXIFEN; TOREMIFENE; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER INHIBITION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; HOT FLUSH; HUMAN; HYPERCALCEMIA; INSOMNIA; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIVER FUNCTION; MITOSIS; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SOFT TISSUE TUMOR; THROMBOEMBOLISM; VAGINA DISCHARGE; VAGINA EPITHELIUM;

EID: 0030695441     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711040-00002     Document Type: Review

References (53)

1. Harper MJK, Walpole AL, Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenyl- ethylenes. Nature 1966; 212: 87
2. Legha SS, Carter SK. Antiestrogens in the treatment of breast cancer. Cancer Treat Rev 1976; 3: 205-16
3. Saez RA, Osborne CK. Hormonal treatment of advanced breast cancer. In: Kennedy BJ, editor. Current clinical oncology. New York: Alan R. Liss Inc., 1989: 163-72
4. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127-205
5. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31.000 recurrences and 24.000 deaths among 75.000 women. Lancet 1992; 339: 1-15, 71-85
6. Wiebe VJ, Osborne CK, Fuqua SAW, et al. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993; 14: 173-88
7. Fornander T, Cedermark B, Matsson A, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 11: 117-20
8. Fisher B, Costantino JP, Redmont CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37
9. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645-51
10. Kallio S, Kangas L, Blanco G, et al. A new triphenylethylene compound, Fc-1157a: I. Hormonal effects. Cancer Chemother Pharmacol 1986; 17: 103-8
11. Kivinen S, Mäenpää J. Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase 1 study. J Steroid Biochem 1990; 36: 217-20
12. Mäenpää J, Söderström K-O, Grönroos M, et al. Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women. J Steroid Biochem 1990; 36: 221-3
13. Szamel I, Vincze B, Hindy I, et al. Hormonal effects of toremifene in breast cancer patients. J Steroid Biochem 1990; 36: 243-7
14. Hamm JT, Tormey DC, Kohler PC, et al. Phase 1 study of toremifene in patients with advanced cancer. J Clin Oncol 1991; 9: 2036-41
15. Szamel I, Hindy I, Vincze B, et al. Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer 1994; 30A: 154-8
16. Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996; 14: 429-33
17. Anttila M, Valavaara R, Kivinen S, et al. Pharmacokinetics of toremifene. J Steroid Biochem 1990; 36: 249-52
18. Wiebe VJ, Benz CC, Shemano I, et al. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 1990; 25: 247-51
19. Kohler PC, Hamm JT, Wiebe VJ, et al. Phase 1 study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res Treat 1990; 16 Suppl.: 19-26
20. Bishop J, Murray R, Webster L, et al. Phase 1 clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 1992; 30: 174-8
21. Anttila M, Laakso S, Nyländen P, et al. Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther 1995; 57: 628-35
22. Kangas L, Nieminen A-L, Blanco G, et al. A new triphenyl- ethylene compound, Fc-1157a: II. Antitumor effects. Cancer Chemother Pharmacol 1986; 17: 109-13
23. Wärri AM, Huovinen RL, Laine AM, et al. Apoptosis in toremifene-induced growth inhibition of human breast cancel cells in vivo and in vitro. J Natl Cancer Inst 1993; 85: 1412-8
24. Iino Y, Takai Y, Ando T, et al. Effect of toremifene on the growth, hormone receptors and insulin-like growth factor-1 of hormone-dependent MCF-7 tumors in athymic mice. Cancer Chemother Pharmacol 1993; 32: 353-8
25. Valavaara R, Pyrhönen S. Low-dose toremifene in the treatment of estrogen receptor-positive advanced breast cancer in postmenopausal women. Curr Ther Res 1989; 46: 966-73
26. Valavaara R, Pyrhönen S, Heikkinen M,et al. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer: phase II study. Eur J Cancer Clin Oncol 1988; 24: 785-90
27. Gundersen S. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancel: a phase II study. J Steroid Biochem 1990; 36: 233-4
28. Modig H, Borgström S, Nilsson I, et al. Phase II clinical sludy of toremifene in patients with metastatic breast cancer: preliminary communication. J Steroid Biochem 1990; 36: 235-6
29. Hietanen T, Baltina D, Johansson R, et al. High dose toremifene (240 mg: daily) is effective as first line hormonal treatment in advanced breast cancel: an ongoing phase II multicenter Finnish-Latvian cooperative study. Breast Cancer Res Treat 1990; 16 Suppl.: 37-40
30. Valavaara R, Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 1990; 16 Suppl.: 31-5
31. Valavaara R, Tuominen J, Johansson R. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer 1990; 66: 2264-9
32. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancel. J Clin Oncol 1995; 13: 2556-66
33. Perry JJ, Berry DA, Weiss RB, et al. High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB). Breast Cancer Res Treat 1995; 36: 35-40
34. Kellen JA, Georges E, Ling V, et al. Toremifene resistance in a rat mammary tumour model. Anticancer Res 1992; 12: 1663-5
35. Ebbs SR, Roberts J, Baum M. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer: preliminary communication. J Steroid Biochem 1990; 36: 239
36. Modig H, Borgström S, Nilsson I, et al. Phase II clinical study ot high-dose toremifene in patients with advanced breast cancer. J Steroid Biochem 1990; 36: 237-8
37. Jonsson PE, Malmberg M, Bergljung L, et al. Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment. Anticancer Res 1991; 11: 873-5
38. Vogel CL, Shemano I, Schoenfelder J, et al. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol 1993; 11: 345-50
39. Stenbygaard LE, Herrstedt J, Thomsen JL, et al. Toremifene and tamoxifen in advanced breast cancer a double-blind cross- over trial. Breast Cancer Res Treat 1993; 25: 57-63
40. Pyrhönen S, Valavaara R, Vuorinen J, et al. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 1994; 29: 223-8
41. Bruning PF. Droloxifene, a new anti-estrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 1992; 28A: 1404-7
42. Rauschning W, Pritchard KI. Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat 1994; 31: 83-94
43. Tomas E, Kauppila A, Blanco G, et al. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995; 59: 261-6
44. Hirsimäki P, Hirsimäki Y, Nieminen L, et al. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol 1993; 67: 49-54
45. White IN, deMatteis F, Davies A, et al. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 1992; 13: 2197-203
46. Hemminki K, Widlak P, Hou S-M. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 1995; 16: 1661-4
47. Cunningham A, Klopman G, Rosenkranz HS. A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and then metabolites. Mutat Res 1996; 349: 85-94
48. Davies AM, Martin EA, Jones RM, et al. Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis 1995; 16: 539-45
49. Sargent LM, Dragan YP, Sattler C, et al. Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis 1996; 17: 1051-6
50. Styles JA, Davies A, Davies R, et al. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). Carcinogenesis 1997; 18: 303-13
51. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860-4
52. Valavaara R, Tuominen J, Toivanen A. The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene. Cancer Immunol Immunother 1990; 31: 381-6
53. Paavonen T, Aronen H, Pyrhönen S, et al. The effect of toremifene therapy on serum immunoglobulin levels in breast cancer. APMIS 1991; 99: 849-53